New drug bempedoic acid emerges as option for hard-to-treat heart disease

International lipid experts have endorsed bempedoic acid as a treatment for patients who cannot tolerate or respond to standard cholesterol drugs. The position paper signals growing clinical acceptance of the medication, which could expand the market for heart disease management and create new revenue streams for pharmaceutical companies targeting the estimated millions of patients with difficult-to-control cardiovascular risk.

Originaltitel: Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)